Fred C. Kass, MD, oncology/hematology, internal medicine, Cancer Center of Santa Barbara, discusses HER2-positive breast cancer advancements.
Kass says the adjuvant setting has produced positive results, which has allowed he and his colleagues to effectively palliate metastatic patients better than ever before. However, optimal sequencing is still being determined.
Some metastatic malignancies can now be managed as chronic illnesses, says Kass. By being able to control these malignancies, Kass and his colleagues are now seeing recurrences of metastases to the central nervous system (CNS) as the limiting factor for quality and quantity of life.
Fred C. Kass, MD, oncology/hematology, internal medicine, Cancer Center of Santa Barbara, discusses HER2-positive breast cancer advancements.
Sequencing Sacituzumab and Other Drugs in HR+, HER2- Breast Cancer
May 16th 2024During a Case-Based Roundtable® event, Stephanie L. Graff, MD, discussed multiple later-line treatment options in hormone receptor–positive breast cancer with participants in the first article of a 2-part series.
Read More